Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 backgroundMerryl Rodrigues, Toshifumi Yokota|Scientific Reports|2016Cited by 58
Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating PeptideUmme Sabrina Haque, Toshifumi Yokota|Cells|2023Cited by 36
Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASOUmme Sabrina Haque, Toshifumi Yokota, Melissa Kohut|Current Research in Toxicology|2024Cited by 33
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and ChallengesUmme Sabrina Haque, Toshifumi Yokota|Genes|2024Cited by 17
Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging TherapiesUmme Sabrina Haque, Toshifumi Yokota|Degenerative Neurological and Neuromuscular Disease|2025Cited by 9